Patterns of failure for patients with glioblastoma following O-(2-[18F]fluoroethyl)-L-tyrosine PET- and MRI-guided radiotherapy

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Patterns of failure for patients with glioblastoma following O-(2-[18F]fluoroethyl)-L-tyrosine PET- and MRI-guided radiotherapy. / Lundemann, Michael; Costa, Junia Cardoso; Law, Ian; Engelholm, Svend Aage; Muhic, Aida; Poulsen, Hans Skovgaard; Munck af Rosenschöld, Per.

In: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, Vol. 122, No. 3, 03.2017, p. 380-386.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Lundemann, M, Costa, JC, Law, I, Engelholm, SA, Muhic, A, Poulsen, HS & Munck af Rosenschöld, P 2017, 'Patterns of failure for patients with glioblastoma following O-(2-[18F]fluoroethyl)-L-tyrosine PET- and MRI-guided radiotherapy', Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, vol. 122, no. 3, pp. 380-386. https://doi.org/10.1016/j.radonc.2017.01.002

APA

Lundemann, M., Costa, J. C., Law, I., Engelholm, S. A., Muhic, A., Poulsen, H. S., & Munck af Rosenschöld, P. (2017). Patterns of failure for patients with glioblastoma following O-(2-[18F]fluoroethyl)-L-tyrosine PET- and MRI-guided radiotherapy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 122(3), 380-386. https://doi.org/10.1016/j.radonc.2017.01.002

Vancouver

Lundemann M, Costa JC, Law I, Engelholm SA, Muhic A, Poulsen HS et al. Patterns of failure for patients with glioblastoma following O-(2-[18F]fluoroethyl)-L-tyrosine PET- and MRI-guided radiotherapy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2017 Mar;122(3):380-386. https://doi.org/10.1016/j.radonc.2017.01.002

Author

Lundemann, Michael ; Costa, Junia Cardoso ; Law, Ian ; Engelholm, Svend Aage ; Muhic, Aida ; Poulsen, Hans Skovgaard ; Munck af Rosenschöld, Per. / Patterns of failure for patients with glioblastoma following O-(2-[18F]fluoroethyl)-L-tyrosine PET- and MRI-guided radiotherapy. In: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2017 ; Vol. 122, No. 3. pp. 380-386.

Bibtex

@article{db4e47d55319445d8b7b75c41c6d3f2d,
title = "Patterns of failure for patients with glioblastoma following O-(2-[18F]fluoroethyl)-L-tyrosine PET- and MRI-guided radiotherapy",
abstract = "BACKGROUND AND PURPOSE: To evaluate the patterns of failure following clinical introduction of amino-acid O-(2-[18F]fluoroethyl)-L-tyrosine (FET)-PET-guided target definition for radiotherapy (RT) of glioblastoma patients.MATERIALS AND METHODS: The first 66 consecutive patients with confirmed histology, scanned using FET-PET/CT and MRI were selected for evaluation. Chemo-radiotherapy was delivered to a volume based on both MRI and FET-PET (PETvol). The volume of recurrence (RV) was defined on MRI data collected at the time of progression according to RANO criteria.RESULTS: Fifty patients were evaluable, with median follow-up of 45months. Central, in-field, marginal and distant recurrences were observed for 82%, 10%, 2%, and 6% of the patients, respectively. We found a volumetric overlap of 26%, 31% and 39% of the RV with the contrast-enhancing MR volume, PETvol and the composite MRPETvol, respectively. MGMT-methylation (p=0.03), larger PETvol (p<0.001), and less extensive surgery (p<0.001), were associated with larger PETvol overlap.CONCLUSION: The combined MRPETvol had a stronger association with the recurrence volume than either of the modalities alone. Larger overlap of PETvol and RV was observed for patients with MGMT-methylation, less extensive surgery, and large PETvol on the RT-planning scans.",
keywords = "Adult, Aged, Aged, 80 and over, Brain Neoplasms, Disease Progression, Female, Glioblastoma, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Neoplasm Recurrence, Local, Positron Emission Tomography Computed Tomography, Positron-Emission Tomography, Radiology, Interventional, Radiopharmaceuticals, Radiotherapy, Image-Guided, Retrospective Studies, Treatment Failure, Tyrosine, Journal Article",
author = "Michael Lundemann and Costa, {Junia Cardoso} and Ian Law and Engelholm, {Svend Aage} and Aida Muhic and Poulsen, {Hans Skovgaard} and {Munck af Rosensch{\"o}ld}, Per",
note = "Copyright {\textcopyright} 2017 Elsevier B.V. All rights reserved.",
year = "2017",
month = mar,
doi = "10.1016/j.radonc.2017.01.002",
language = "English",
volume = "122",
pages = "380--386",
journal = "Radiotherapy & Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

RIS

TY - JOUR

T1 - Patterns of failure for patients with glioblastoma following O-(2-[18F]fluoroethyl)-L-tyrosine PET- and MRI-guided radiotherapy

AU - Lundemann, Michael

AU - Costa, Junia Cardoso

AU - Law, Ian

AU - Engelholm, Svend Aage

AU - Muhic, Aida

AU - Poulsen, Hans Skovgaard

AU - Munck af Rosenschöld, Per

N1 - Copyright © 2017 Elsevier B.V. All rights reserved.

PY - 2017/3

Y1 - 2017/3

N2 - BACKGROUND AND PURPOSE: To evaluate the patterns of failure following clinical introduction of amino-acid O-(2-[18F]fluoroethyl)-L-tyrosine (FET)-PET-guided target definition for radiotherapy (RT) of glioblastoma patients.MATERIALS AND METHODS: The first 66 consecutive patients with confirmed histology, scanned using FET-PET/CT and MRI were selected for evaluation. Chemo-radiotherapy was delivered to a volume based on both MRI and FET-PET (PETvol). The volume of recurrence (RV) was defined on MRI data collected at the time of progression according to RANO criteria.RESULTS: Fifty patients were evaluable, with median follow-up of 45months. Central, in-field, marginal and distant recurrences were observed for 82%, 10%, 2%, and 6% of the patients, respectively. We found a volumetric overlap of 26%, 31% and 39% of the RV with the contrast-enhancing MR volume, PETvol and the composite MRPETvol, respectively. MGMT-methylation (p=0.03), larger PETvol (p<0.001), and less extensive surgery (p<0.001), were associated with larger PETvol overlap.CONCLUSION: The combined MRPETvol had a stronger association with the recurrence volume than either of the modalities alone. Larger overlap of PETvol and RV was observed for patients with MGMT-methylation, less extensive surgery, and large PETvol on the RT-planning scans.

AB - BACKGROUND AND PURPOSE: To evaluate the patterns of failure following clinical introduction of amino-acid O-(2-[18F]fluoroethyl)-L-tyrosine (FET)-PET-guided target definition for radiotherapy (RT) of glioblastoma patients.MATERIALS AND METHODS: The first 66 consecutive patients with confirmed histology, scanned using FET-PET/CT and MRI were selected for evaluation. Chemo-radiotherapy was delivered to a volume based on both MRI and FET-PET (PETvol). The volume of recurrence (RV) was defined on MRI data collected at the time of progression according to RANO criteria.RESULTS: Fifty patients were evaluable, with median follow-up of 45months. Central, in-field, marginal and distant recurrences were observed for 82%, 10%, 2%, and 6% of the patients, respectively. We found a volumetric overlap of 26%, 31% and 39% of the RV with the contrast-enhancing MR volume, PETvol and the composite MRPETvol, respectively. MGMT-methylation (p=0.03), larger PETvol (p<0.001), and less extensive surgery (p<0.001), were associated with larger PETvol overlap.CONCLUSION: The combined MRPETvol had a stronger association with the recurrence volume than either of the modalities alone. Larger overlap of PETvol and RV was observed for patients with MGMT-methylation, less extensive surgery, and large PETvol on the RT-planning scans.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Brain Neoplasms

KW - Disease Progression

KW - Female

KW - Glioblastoma

KW - Humans

KW - Magnetic Resonance Imaging

KW - Male

KW - Middle Aged

KW - Neoplasm Recurrence, Local

KW - Positron Emission Tomography Computed Tomography

KW - Positron-Emission Tomography

KW - Radiology, Interventional

KW - Radiopharmaceuticals

KW - Radiotherapy, Image-Guided

KW - Retrospective Studies

KW - Treatment Failure

KW - Tyrosine

KW - Journal Article

U2 - 10.1016/j.radonc.2017.01.002

DO - 10.1016/j.radonc.2017.01.002

M3 - Journal article

C2 - 28110959

VL - 122

SP - 380

EP - 386

JO - Radiotherapy & Oncology

JF - Radiotherapy & Oncology

SN - 0167-8140

IS - 3

ER -

ID: 186635166